First line chemotherapy for low or high risk metastatic breast cancer (LR/HR-MBC) — Are 3 (CMF/FEC) or 2 (NDOC) agents better than 1 (N)? — A multicenter clinical trial of the “IMA”

✍ Scribed by Souchon, R.; Heidemann, E.; Hirschmann, W.; Minckwitz, G.v.

• Book ID: 122397773
• Publisher: Elsevier Science
• Year: 1999
• Tongue: English
• Weight: 155 KB
• Volume: 35
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/S0959-8049(99)81691-8